Echo IQ Ltd (ASX: EIQ) has expanded its agreement with Mayo Clinic to enable the potential resale and distribution of its heart failure decision support solution, EchoSolv HF, following FDA clearance. I have liked the Echo IQ story from the first time I was introduced to it. The business is operating in a space where clinical validation, regulatory approval, and commercial deployment must align before revenue can be realised.

Echo IQ Limited (ASX: EIQ) is an Australian AI and medical technology company focused on improving decision-making in cardiology. Its lead product, EchoSolv HF, is a heart failure clinical decision support software designed to assist clinicians in detecting heart failure using echocardiogram data. The Company’s recent announcements outline the completion of clinical validation with the Mayo Clinic Platform and the subsequent formal lodgement of an FDA 510(k) submission in the